Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

Leukemia. 2013 Aug;27(8):1769-73. doi: 10.1038/leu.2013.37. Epub 2013 Feb 6.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cell Proliferation / drug effects
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Oxazines / pharmacology*
  • Oxazines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / pharmacology*
  • Pyridines / therapeutic use
  • Receptors, Antigen, B-Cell / antagonists & inhibitors*
  • Receptors, Antigen, B-Cell / metabolism
  • Signal Transduction / drug effects*

Substances

  • Antineoplastic Agents
  • Oxazines
  • Protein Kinase Inhibitors
  • Pyridines
  • Receptors, Antigen, B-Cell
  • fostamatinib